Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Alcoholism, Clinical and Experimental Research|November 6, 2018
Drinking Risk Level Reductions Associated with Improvements in Physical Health and Quality of Life Among Individuals with Alcohol Use DisorderKatie Witkiewitz, Henry R Kranzler, Kevin A Hallgren, et al.
Drug and Alcohol Dependence|June 8, 2019
Reduction in non-abstinent World Health Organization (WHO) drinking risk levels and drug use disorders: 3-year follow-up results in the US general populationJustin Knox, Melanie Wall, Katie Witkiewitz, et al.
Alcoholism, Clinical and Experimental Research|May 5, 2020
Effects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes Among Treatment-Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double-Blind, Placebo-Controlled Clinical Trial of VareniclineRobert Miranda, Stephanie S O'Malley, Hayley Treloar Padovano, et al.
Alcohol, Clinical & Experimental Research|December 3, 2024
Effects of a novel GABA-B positive allosteric modulator, ASP8062, on alcohol cue-elicited craving and naturalistic alcohol consumption in a multisite randomized, double-blind, placebo-controlled trialJoseph P Schacht, Lara A Ray, Robert Miranda, et al.
Alcoholism, Clinical and Experimental Research|March 16, 2017
Temporal Stability of Heavy Drinking Days and Drinking Reductions Among Heavy Drinkers in the COMBINE StudyKatie Witkiewitz, Adam D Wilson, Matthew R Pearson, et al.
JAMA Psychiatry|March 14, 2019
Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical TrialsDaniel E Falk, Stephanie S O'Malley, Katie Witkiewitz, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|September 9, 2011
The Alcohol Clinical Trials Initiative (ACTIVE): purpose and goals for assessing important and salient issues for medications development in alcohol use disordersRaymond F Anton, Raye Z Litten, Daniel E Falk, et al.
Alcohol and Alcoholism (Oxford, Oxfordshire)|January 20, 2025
Preliminary effects of oral ANS-6637, an ALDH2 inhibitor, on cue-induced craving, safety and alcohol consumption among adults with alcohol use disorder: a proof-of-concept, randomized, human laboratory trialStephanie S O'Malley, Robert Miranda, Sarah W Book, et al.
Alcoholism, Clinical and Experimental Research|September 29, 2011
A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patientsRaye Z Litten, Joanne B Fertig, Daniel E Falk, et al.
Journal of Addiction Medicine|June 4, 2013
A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependenceRaye Z Litten, Megan L Ryan, Joanne B Fertig, et al.
Pageof 4